HK1107001A1 - Anti-integrin immunoconjugates, methods of their production and their use - Google Patents

Anti-integrin immunoconjugates, methods of their production and their use

Info

Publication number
HK1107001A1
HK1107001A1 HK07112495.8A HK07112495A HK1107001A1 HK 1107001 A1 HK1107001 A1 HK 1107001A1 HK 07112495 A HK07112495 A HK 07112495A HK 1107001 A1 HK1107001 A1 HK 1107001A1
Authority
HK
Hong Kong
Prior art keywords
production
methods
immunoconjugates
integrin
integrin immunoconjugates
Prior art date
Application number
HK07112495.8A
Other languages
English (en)
Chinese (zh)
Inventor
Qiming Chen
Mohit Trikha
Robert J Lutz
Rita M Steeves
Godfrey Amphlett
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of HK1107001A1 publication Critical patent/HK1107001A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK07112495.8A 2004-12-09 2007-11-15 Anti-integrin immunoconjugates, methods of their production and their use HK1107001A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63444504P 2004-12-09 2004-12-09
PCT/US2005/043250 WO2006062779A2 (en) 2004-12-09 2005-11-30 Anti-integrin immunoconjugates, methods and uses

Publications (1)

Publication Number Publication Date
HK1107001A1 true HK1107001A1 (en) 2008-03-28

Family

ID=36578407

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07112495.8A HK1107001A1 (en) 2004-12-09 2007-11-15 Anti-integrin immunoconjugates, methods of their production and their use

Country Status (25)

Country Link
US (2) US8603483B2 (xx)
EP (1) EP1819359B1 (xx)
JP (1) JP5421532B2 (xx)
KR (1) KR101281501B1 (xx)
CN (1) CN101193916B (xx)
AR (1) AR052041A1 (xx)
AU (1) AU2005314392B2 (xx)
BR (1) BRPI0515745A (xx)
CA (1) CA2591148A1 (xx)
DK (1) DK1819359T3 (xx)
EA (1) EA013323B1 (xx)
ES (1) ES2539126T3 (xx)
HK (1) HK1107001A1 (xx)
HU (1) HUE025449T2 (xx)
IL (1) IL183695A0 (xx)
MX (1) MX2007007011A (xx)
NO (1) NO20073493L (xx)
NZ (1) NZ555601A (xx)
PL (1) PL1819359T3 (xx)
PT (1) PT1819359E (xx)
SG (1) SG158119A1 (xx)
TW (1) TWI400087B (xx)
UA (1) UA94388C2 (xx)
WO (1) WO2006062779A2 (xx)
ZA (1) ZA200705556B (xx)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2325344B1 (es) * 2004-11-02 2010-06-09 Univ Madrid Autonoma Inhibidores de angiogenesis multifuncionales y multivalentes.
ES2539126T3 (es) * 2004-12-09 2015-06-26 Janssen Biotech, Inc. Inmunoconjugados anti integrina, métodos para su producción y su uso
WO2007015128A1 (en) 2005-08-02 2007-02-08 Xbiotech Inc. DIAGNOSIS, TREATMENT, AND PREVENTION OF VASCULAR DISORDERS USING IL-1α AUTOANTIBODIES
BRPI0709338A2 (pt) 2006-03-21 2011-07-12 Genentech Inc anticorpo, molécula de ácido nucleico isolada, célula, composições, método de detecção da proteìna alfa5beta1, uso de anticorpo, métodos de tratamento, kit, uso de uma composição, uso de uma antagonista de alfa5beta e uso de uma antagonista de vegf
BRPI0715141A2 (pt) 2006-08-03 2013-06-04 Astrazeneca Ab agente de ligaÇço alvejante, anticorpo isolado, fragmento de anticorpo isolado, molÉcula de Ácido nucleico, vetor, cÉlula hospedeira, mÉtodos para produzir um agente de ligaÇço alvejado, para produzir um anticorpo, para produzir um fragmento de anticorpo, para tratar um tumor maligno em um animal, para tratar inflamaÇço, e para inibir a interaÇço de alfabeta6 com seu ligando, e, conjugado
US20080081041A1 (en) * 2006-09-29 2008-04-03 Jeffrey Nemeth Method of Using IL6 Antagonists with Mitoxantrone for Prostate Cancer
US20090175784A1 (en) * 2007-05-11 2009-07-09 Joshua Goldstein Anti-Alpha V Immunoliposome Composition, Methods, and Uses
WO2008141276A1 (en) * 2007-05-11 2008-11-20 Centocor, Inc. Anti-alpha-v immunoliposome composition, methods and uses
SI2200700T1 (sl) 2007-09-26 2016-04-29 Genentech, Inc. Nova protitelesa
US8236319B2 (en) 2008-04-30 2012-08-07 Immunogen, Inc. Cross-linkers and their uses
RU2498998C2 (ru) 2008-05-30 2013-11-20 ИксБиотеч, Инк. АНТИТЕЛА К ИНТЕРЛЕЙКИНУ-1α И СПОСОБЫ ПРИМЕНЕНИЯ
CN105085349B (zh) * 2008-07-21 2018-02-09 布赖汉姆妇女医院 与合成的β‑1,6 葡糖胺寡糖相关的方法和组合物
CA2737056C (en) 2008-09-12 2018-10-30 Xbiotech Inc. Targeting pathogenic monocytes
US20110207155A1 (en) * 2008-10-13 2011-08-25 Xeptagen Spa Method for the preparation of immunoconjugates and use thereof
MX2011010012A (es) 2009-03-25 2011-12-06 Genentech Inc NUEVOS ANTICUERPOS ANTI-A5ß1 Y SUS USOS.
CN104984360A (zh) 2009-06-03 2015-10-21 伊缪诺金公司 轭合方法
FR2947269B1 (fr) * 2009-06-29 2013-01-18 Sanofi Aventis Nouveaux composes anticancereux
CA2676946A1 (en) * 2009-08-28 2011-02-28 Lucie Peduto Adam12 inhibitors and their use against inflammation-induced fibrosis
IN2012DN02780A (xx) 2009-10-06 2015-09-18 Immunogen Inc
CN105001334A (zh) 2010-02-10 2015-10-28 伊缪诺金公司 Cd20抗体及其用途
WO2011162933A1 (en) * 2010-06-04 2011-12-29 Immunogen, Inc. Anti-integrin immunoconjugate dosing regimens
AU2011268229B2 (en) 2010-06-18 2015-04-16 Xbiotech Inc. Arthritis treatment
NZ607472A (en) * 2010-08-23 2014-09-26 Xbiotech Inc Treatment for neoplastic diseases
JP6006640B2 (ja) * 2010-10-29 2016-10-12 株式会社ペルセウスプロテオミクス 高い内在化能力を有する抗ｃｄｈ３抗体
KR102272828B1 (ko) 2011-03-29 2021-07-05 이뮤노젠 아이엔씨 일-단계 방법에 의한 메이탄시노이드 항체 접합체의 제조
MY171008A (en) 2011-03-29 2019-09-23 Immunogen Inc Preparation of maytansinoid antibody conjugates by a one-step process
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
RU2610336C2 (ru) 2011-04-21 2017-02-09 Сиэтл Дженетикс, Инк. Новые конъюгаты связывающее соединение - активное соединение (adc) и их применение
RU2013154048A (ru) * 2011-05-09 2015-06-20 Юниверсити Оф Вирджиния Пэтент Фаундейшн Композиции и способы лечения рака
CN108404127A (zh) 2011-09-23 2018-08-17 埃克斯生物科技公司 恶病质治疗
MX2014008373A (es) * 2012-01-27 2014-09-26 Hoffmann La Roche Conjugados antagonistas de integrina para suministro dirigido a celulas que expresan alfa-v-beta-3.
MX360141B (es) * 2012-02-17 2018-10-24 Seattle Genetics Inc Anticuerpos contra integrina alfavhbeta6 y uso de los mismos para tratar cancer.
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
ES2716561T3 (es) * 2012-09-26 2019-06-13 Immunogen Inc Métodos mejorados para la acilación de maitansinol
AU2013326881B2 (en) 2012-10-04 2018-08-02 Immunogen, Inc. Use of a PVDF membrane to purify cell-binding agent cytotoxic agent conjugates
WO2014066002A1 (en) * 2012-10-23 2014-05-01 The Johns Hopkins University Novel self-assembling drug amphiphiles and methods for synthesis and use
CA2898239A1 (en) 2013-01-23 2014-07-31 Syddansk Universitet Mfap4 binding antibodies blocking the interaction between mfap4 and integrin receptors
EP2777714A1 (en) * 2013-03-15 2014-09-17 NBE-Therapeutics LLC Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme
WO2015009948A1 (en) * 2013-07-19 2015-01-22 Regents Of The University Of California Milk fat globule epidermal growth factor 8 regulates fatty acid uptake
BR112016004023A2 (pt) 2013-08-26 2022-11-16 Regeneron Pharma Composição, métodos para preparar uma composição e para tratar uma doença, e, composto
CA2934617A1 (en) 2013-12-23 2015-07-02 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (adcs) with kinesin spindle protein (ksp)
MA42561A (fr) 2014-09-02 2018-04-25 Immunogen Inc Procédés de formulation de compositions de conjugués anticorps-médicament
SG11201703599VA (en) 2014-11-19 2017-06-29 Immunogen Inc Process for preparing cell-binding agent-cytotoxic agent conjugates
EP4289483A3 (en) 2014-12-04 2024-02-28 Celgene Corporation Biomolecule conjugates
WO2016102679A1 (en) 2014-12-23 2016-06-30 Nbe-Therapeutics Ag Binding protein drug conjugates comprising anthracycline derivatives
JP6971858B2 (ja) 2015-06-22 2021-11-24 バイエル ファーマ アクチエンゲゼルシャフト 酵素開裂性基を有する抗体薬物複合体（ａｄｃ）および抗体プロドラッグ複合体（ａｐｄｃ）
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
EP3411077A1 (en) 2016-02-05 2018-12-12 ImmunoGen, Inc. Efficient process for preparing cell-binding agent-cytotoxic agent conjugates
GB201602356D0 (en) * 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
MX2018011627A (es) 2016-03-24 2019-01-10 Bayer Pharma AG Profarmacos de farmacos citotoxicos que tienen grupos enzimaticamente escindibles.
CN109310781B (zh) 2016-06-15 2024-06-18 拜耳制药股份公司 具有ksp抑制剂和抗-cd123-抗体的特异性抗体-药物-缀合物(adc)
JP7066714B2 (ja) 2016-12-21 2022-05-13 バイエル・ファルマ・アクティエンゲゼルシャフト 酵素的に切断可能な基を有する抗体薬物コンジュゲート（ａｄｃ）
EP3558387B1 (de) 2016-12-21 2021-10-20 Bayer Pharma Aktiengesellschaft Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren
CA3047491A1 (en) 2016-12-21 2018-06-28 Bayer Aktiengesellschaft Prodrugs of cytotoxic active agents having enzymatically cleavable groups
MX2019009798A (es) 2017-02-16 2020-01-30 Xbiotech Inc Tratamiento de la hidradenitis supurativa.
US10639382B2 (en) 2017-04-13 2020-05-05 National Guard Health Affairs Method for treating leukemia
CA3063439A1 (en) * 2017-05-30 2018-12-06 The Board Of Trustees Of The Leland Stanford Junior University Treatment of neuroinflammatory disease
CN110891605A (zh) * 2017-06-07 2020-03-17 希沃尔拜克治疗公司 免疫调节化合物的抗体缀合物及其用途
US20200046737A1 (en) 2018-08-09 2020-02-13 Notable Labs, Inc. Methods for treating cancer, and compositions therefor
EP3996749A1 (en) 2019-07-10 2022-05-18 Cybrexa 3, Inc. Peptide conjugates of microtubule-targeting agents as therapeutics
TW202116778A (zh) 2019-07-10 2021-05-01 美商斯布雷克薩二號公司 作為治療劑之細胞毒素之肽結合物
WO2024001669A1 (zh) * 2022-06-27 2024-01-04 昱言科技(北京)有限公司 靶向itga2的抗体和包含此抗体的抗体药物缀合物
CN115350187B (zh) * 2022-08-30 2023-08-29 中山大学 异丙托溴铵在抑制肺癌骨转移中的应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
SE430062B (sv) 1977-03-04 1983-10-17 Pharmacia Fine Chemicals Ab Kopplings- eller tioleringsreagens
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
CA2026147C (en) * 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2452130A1 (en) 1992-03-05 1993-09-16 Francis J. Burrows Methods and compositions for targeting the vasculature of solid tumors
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
JP3161490B2 (ja) 1993-07-30 2001-04-25 松下電器産業株式会社 金型装置
US6160099A (en) 1998-11-24 2000-12-12 Jonak; Zdenka Ludmila Anti-human αv β3 and αv β5 antibodies
GB9909392D0 (en) 1999-04-24 1999-06-23 Imp Cancer Res Tech Treatment, imaging and diagnosis of disease
BRPI0012196B8 (pt) 1999-06-25 2021-05-25 Genentech Inc artigo industrializado
US7163681B2 (en) 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
AR030612A1 (es) 2000-09-12 2003-08-27 Smithkline Beecham Corp Procedimiento e intermedios
US20030003048A1 (en) * 2001-04-26 2003-01-02 Chun Li Diagnostic imaging compositions, their methods of synthesis and use
EP1258255A1 (en) 2001-05-18 2002-11-20 Boehringer Ingelheim International GmbH Conjugates of an antibody to CD44 and a maytansinoid
US20030103985A1 (en) 2001-05-18 2003-06-05 Boehringer Ingelheim International Gmbh Cytotoxic CD44 antibody immunoconjugates
US6441163B1 (en) * 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
EP1507781A4 (en) 2002-05-13 2006-03-15 Smithkline Beecham Corp METHOD OF PREPARING MAYTANSINOL
AU2003259163B2 (en) 2002-08-16 2008-07-03 Immunogen, Inc. Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs
EP2281577B1 (en) * 2003-05-14 2016-11-16 ImmunoGen, Inc. Drug conjugate composition
WO2004103272A2 (en) 2003-05-20 2004-12-02 Immunogen, Inc. Improved cytotoxic agents comprising new maytansinoids
US7276497B2 (en) * 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
ES2539126T3 (es) * 2004-12-09 2015-06-26 Janssen Biotech, Inc. Inmunoconjugados anti integrina, métodos para su producción y su uso

Also Published As

Publication number Publication date
PL1819359T3 (pl) 2015-08-31
AU2005314392B2 (en) 2011-04-14
WO2006062779A3 (en) 2008-01-17
ZA200705556B (en) 2008-12-31
ES2539126T3 (es) 2015-06-26
DK1819359T3 (en) 2015-04-20
WO2006062779A2 (en) 2006-06-15
CN101193916B (zh) 2012-09-05
AU2005314392A1 (en) 2006-06-15
SG158119A1 (en) 2010-01-29
US20060127407A1 (en) 2006-06-15
TWI400087B (zh) 2013-07-01
IL183695A0 (en) 2007-09-20
US20140093523A1 (en) 2014-04-03
US8603483B2 (en) 2013-12-10
MX2007007011A (es) 2007-09-21
EA013323B1 (ru) 2010-04-30
NZ555601A (en) 2009-07-31
HUE025449T2 (en) 2016-04-28
EA200701250A1 (ru) 2008-06-30
KR101281501B1 (ko) 2013-07-15
EP1819359A2 (en) 2007-08-22
PT1819359E (pt) 2015-05-28
EP1819359B1 (en) 2015-03-18
JP5421532B2 (ja) 2014-02-19
UA94388C2 (ru) 2011-05-10
TW200635606A (en) 2006-10-16
AR052041A1 (es) 2007-02-28
KR20070089220A (ko) 2007-08-30
CN101193916A (zh) 2008-06-04
CA2591148A1 (en) 2006-06-15
NO20073493L (no) 2007-09-06
EP1819359A4 (en) 2010-04-28
BRPI0515745A (pt) 2008-08-05
JP2008523062A (ja) 2008-07-03

Similar Documents

Publication Publication Date Title
HK1107001A1 (en) Anti-integrin immunoconjugates, methods of their production and their use
EP1743174A4 (en) MULTIMODALITY NANOSTRUCTURES, METHODS OF MAKING AND USING THE SAME
EP2076326A4 (en) CE-ZR-R-O-CATALYSTS, ARTICLES WITH THE CE-ZR-R-O-CATALYSTS, AND METHOD FOR THE PRODUCTION AND USE OF THE CE-ZR-R-O-CATALYSTS
EP2046391A4 (en) DRUG VECTORS, THEIR SYNTHESIS, AND METHODS FOR THEIR USE
ZA200705951B (en) Hydroprocessing catalyst, preparation method thereof and use of same
ZA200710173B (en) Tygecycline and methods of preparing 9-nitrominocycline
IL213843A0 (en) 4-aminotetracyclines and methods of use thereof
IL185785A0 (en) Certain substituted amides, method of making, and method of use thereof
HK1124321A1 (en) Substituted 4-phenyltetrahydroisoquinolines, method of producing them, their use as medicament, and also medicament containing them
IL180682A0 (en) N-hydroxamide derivatives, their preparation and use
IL180284A0 (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
EP1863769A4 (en) HSP90 INHIBITORS, METHOD FOR THE PRODUCTION THEREOF AND THEIR APPLICATIONS
EP1979269A4 (en) CHLORINE FORMULATIONS AND PROCESS FOR THE PREPARATION AND USE THEREOF
EP1797186A4 (en) EXPRESSION SYSTEM, ITS COMPONENTS AND USE METHOD
IL180770A0 (en) Oxopiperidine derivatives, preparation and therapeutic use thereof
IL180797A0 (en) Amino-tropane derivatives, preparation thereof and therapeutic use thereof
IL183136A0 (en) Modified alginates, methods of production and use
IL190519A0 (en) 6-heteroarylpyridoindolone derivatives, their preparation and therapeutic use thereof
HK1113686A1 (en) Biotinylated hexadecasaccharides, preparation and use thereof
PL1683840T3 (pl) Odporne na redukcję pigmenty oparte na ferrycie cynkowym, sposób ich wytwarzania i ich zastosowanie
IL177759A0 (en) Cospeptin, cosmedin and their uses
EP1978999A4 (en) ISOLATED MCPIP PROTEIN AND METHODS OF USE
IL187419A0 (en) Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents
HK1107340A1 (en) 4-arylmorpholin-3-one derivatives, preparation and therapeutic use thereof
ZA200608279B (en) Synthetic chemokines, methods of manufacture, and uses

Legal Events

Date Code Title Description
AM Amended specification (according sect 146 of patent law)

Free format text: CORRECTION OF THE NAME OF APPLICANT FROM JANSSEN BIOTECH INC. TO JANSSEN BIOTECH, INC..

Effective date: 20111116

PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20191130